Xeris and Strongbridge are now subsidiaries of Xeris Biopharma Holdings, Inc.
DeepUll is a portfolio company of Pertinence Invest 2 Fund (managed by UI Investissement, formerly Sofimac Innovation).
MH002 is the first rationally-designed consortium therapy, in which key disease-driving mechanisms guide therapeutic microbial strain selection, to...
ecoation is a pioneer in robotics and artificial intelligence technologies for horticulture
The deal is expected to close by the end of 2021.
Mimetas will develop tissue-based disease models and assays in the OrganoPlate
MxEP will be present at IPEM 2021, on September 8th and 9th at Hippodrome de Longchamp (Paris). Meet our GBO and VC teams in the salon Goldikova...
Mérieux Participations 4 fund (MP4) has joined the vehicle majority owned by Yves Journel, founder of DomusVi, to enter the capital of the Group.
Michael Brownell brings 30 years of international experience with innovative businesses and new product development in ophthalmology.